AstraZeneca plc vs Barclays PLC — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while Barclays PLC trades at $27.87 (market cap $94.10B). The key difference: AstraZeneca plc is far larger — about 2.7× Barclays PLC's market cap, and Barclays PLC pays the higher dividend (2.18%). Which is the better fit depends on your goals.
| AZN | BCS | |
|---|---|---|
Market Cap | $250.84B | $94.10B |
Sector | Health | Financials |
52-Week High | $209.48 | $28.56 |
52-Week Low | $147.06 | $19.36 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | 2.18% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →